remdesivir
rdv
nucleotid
prodrug
intracellularli
metabol
analog
adenosin
triphosph
inhibit
viral
rna
polymeras
broad
spectrum
activ
member
filovirus
provid
document
singl
patient
protocol
use
rdv
treatment
patient
coronaviru
result
infect
recommend
use
rdv
treatment
base
vitro
vivo
activ
rdv
human
highli
pathogen
cov
merscov
sarscov
recent
result
initi
vitro
test
perform
china
cdc
collabor
gilead
show
rdv
potent
antivir
activ
vero
cell
preliminari
data
anoth
studi
conduct
wuhan
institut
virolog
rdv
also
show
vitro
activ
vero
cell
wang
gilead
note
studi
wuhan
institut
virolog
conduct
extern
drug
suppli
gilead
research
us
china
continu
test
rdv
clinic
isol
use
drug
suppli
gilead
multipl
relev
cell
type
known
effici
metabol
rdv
activ
triphosph
form
compar
vero
cell
remdesivir
accept
nonclin
toler
safeti
profil
exhibit
vivo
prophylact
therapeut
efficaci
sarscov
merscov
infect
mice
merscov
infect
rhesu
monkey
addit
rdv
shown
gener
safe
toler
safeti
databas
individu
receiv
rdv
date
key
attribut
rdv
nonclin
clinic
profil
support
use
emerg
treatment
follow
initi
vitro
test
perform
china
cdc
collabor
gilead
show
rdv
potent
antivir
activ
vero
cell
remdesivir
show
potent
vitro
activ
human
pathogen
coronavirus
merscov
sarscov
multipl
relev
human
cell
type
pharmacokinet
pk
profil
rdv
nonhuman
primat
nhp
relev
anim
speci
indic
high
persist
level
pharmacolog
activ
nucleosid
triphosph
metabolit
peripher
blood
mononuclear
cell
pbmc
support
daili
intraven
iv
administr
infus
remdesivir
demonstr
prophylact
therapeut
efficaci
mous
model
sarscov
pathogenesi
administr
mgkg
rdv
subcutan
twice
daili
begin
day
day
sarscov
inocul
result
significantli
reduc
lung
viral
load
improv
clinic
sign
diseas
well
lung
function
sheahan
mous
model
merscov
pathogenesi
prophylact
therapeut
administr
mgkg
rdv
subcutan
twice
daili
improv
pulmonari
function
reduc
lung
viral
load
sever
lung
patholog
contrast
prophylact
lopinavirritonavir
interferon
beta
lpvrtvifnb
slightli
reduc
viral
load
without
impact
diseas
paramet
therapeut
lpvrtvifnb
improv
pulmonari
function
reduc
viru
replic
sever
lung
patholog
sheahan
remdesivir
also
show
prophylact
therapeut
efficaci
merscovinfect
rhesu
monkey
indian
origin
administr
rdv
mgkg
see
rdv
investig
brochur
ib
mgkg
daili
use
iv
bolu
inject
begin
day
prior
merscov
inocul
result
signific
reduct
clinic
score
clinic
sign
respiratori
diseas
viral
rna
level
compar
vehicletr
anim
therapeut
rdv
treatment
mgkg
daili
day
use
iv
bolu
inject
initi
hour
postinocul
also
result
reduc
clinic
sign
reduc
viru
replic
lung
decreas
presenc
sever
lung
lesion
de
wit
target
organ
identifi
repeatdos
toxicolog
studi
kidney
rat
monkey
clinic
chemistri
urinalysi
urin
biomark
earli
indic
revers
microscop
chang
observ
kidney
remdesivir
favor
clinic
safeti
profil
base
approxim
individu
receiv
rdv
primarili
healthi
volunt
phase
studi
individu
acut
ebov
infect
unknown
present
observ
efficaci
rdv
anim
model
coronaviru
infect
translat
clinic
efficaci
patient
symptomat
diseas
refer
safeti
inform
overview
nonclin
experi
overview
clinic
experi
investig
guidanc
physic
chemic
pharmaceut
inform
provid
rdv
ib
provid
inform
regard
patient
diseasecondit
medic
histori
previou
treatment
remdesivir
singl
diastereom
monophosphoramid
prodrug
nucleosid
analog
coronaviru
infect
progress
sever
lifethreaten
stage
diseas
involv
sever
pneumonia
acut
respiratori
distress
syndrom
case
treatment
rdv
might
limit
impact
surviv
infect
subject
order
maxim
impact
viral
replic
chanc
success
outcom
import
initi
patient
treatment
rdv
soon
possibl
follow
diagnosi
identifi
cov
infect
remdesivir
may
administ
accord
applic
local
regulatori
requir
intraven
iv
infus
administ
minut
period
solut
formul
remdesivir
suppli
steril
preservativefre
clear
colorless
yellow
aqueousbas
concentr
solut
contain
mgml
remdesivir
dilut
infus
fluid
prior
iv
administr
suppli
steril
product
singleus
clear
glass
vial
suffici
volum
allow
withdraw
ml
mg
remdesivir
addit
activ
ingredi
solut
formul
remdesivir
contain
follow
inact
ingredi
water
inject
sulfobutyleth
sodium
sbecd
hydrochlor
acid
andor
sodium
hydroxid
hydrochlor
acid
andor
sodium
hydroxid
use
adjust
formul
final
ph
lyophil
formul
remdesivir
preservativefre
white
offwhit
yellow
lyophil
solid
contain
remdesivir
reconstitut
steril
water
inject
dilut
iv
infus
fluid
prior
iv
administr
suppli
steril
product
singleus
clear
glass
vial
follow
reconstitut
vial
contain
mgml
remdesivir
concentr
solut
suffici
volum
allow
withdraw
ml
mg
remdesivir
addit
activ
ingredi
lyophil
formul
remdesivir
contain
follow
inact
ingredi
water
inject
sbecd
hydrochlor
acid
andor
sodium
hydroxid
hydrochlor
acid
andor
sodium
hydroxid
use
adjust
formul
final
ph
detail
inform
regard
studi
drug
administr
reconstitut
dilut
instruct
provid
pharmaci
manual
provid
investig
propos
regimen
treatment
establish
cov
infect
includ
sarscov
merscov
follow
singl
rdv
mg
iv
load
dose
day
treatment
follow
mg
iv
oncedaili
mainten
dose
day
recommend
rdv
dose
durat
total
day
propos
dose
regimen
base
clinic
safeti
data
approxim
individu
includ
healthi
volunt
individu
acut
ebov
infect
individu
expos
ebov
well
ebola
survivor
support
data
efficaci
studi
mersinfect
rhesu
monkey
treat
rdv
studi
nonclin
studi
rdv
administ
mgkg
studi
mgkg
studi
daili
day
use
iv
bolu
inject
begin
either
day
prior
mgkg
mgkg
dose
hour
transient
treatmentemerg
elev
alt
ast
observ
studi
none
grade
singleascend
dose
studi
grade
grade
multipledos
studi
alt
ast
elev
associ
grade
pt
elev
howev
grade
chang
inr
laboratori
result
subject
indic
system
sign
drug
reaction
overal
clinic
relev
consist
pattern
laboratori
abnorm
chang
baselin
laboratori
paramet
note
studi
addit
detail
avail
ib
toxicolog
studi
cynomolgu
monkey
rat
safeti
pharmacokinet
studi
healthi
volunt
safeti
data
individu
support
safeti
propos
dose
propos
pediatr
dose
regimen
aim
achiev
daili
therapeut
exposur
rdv
compar
adult
consid
risk
benefit
profil
renal
elimin
metabolit
may
accumul
pediatr
patient
immatur
clearanc
pathway
end
physiologicallybas
pharmacokinet
model
simcyp
develop
model
adult
rdv
exposur
predict
pediatr
patient
exposur
base
agedepend
physiolog
chang
eg
organ
volumefunct
blood
flow
etc
simul
account
impact
infect
pharmacokinet
current
unknown
result
simul
indic
pediatr
patient
bodi
weight
kg
adult
dosag
regimen
one
load
dose
rdv
mg
iv
infus
min
day
follow
rdv
mg
iv
infus
min
daili
day
administ
use
adult
dose
pediatr
patient
expect
maintain
exposur
rdv
previous
observ
gener
well
toler
multipl
dose
studi
adult
healthi
volunt
studi
pediatr
patient
bodi
weight
kg
bodi
weightbas
dose
regimen
one
load
dose
rdv
mgkg
iv
infus
min
day
follow
rdv
mgkg
iv
infus
min
daili
day
administ
use
weightbas
regimen
expect
maintain
rdv
exposur
compar
observ
adult
limit
exposur
young
children
specif
studi
conduct
rdv
patient
renal
andor
hepat
impair
substanti
proport
patient
acut
ebola
viru
diseas
receiv
treatment
rdv
palm
meuri
protocol
moder
sever
liver
renal
abnorm
present
renal
hepat
abnorm
attribut
rdv
given
benefitrisk
ratio
patient
acut
cov
infect
dose
modif
recommend
present
time
describ
clinic
procedur
laboratori
test
monitor
necessari
evalu
effect
drug
minim
risk
treatment
rdv
patient
admit
inpati
facil
staf
maintain
request
physician
peripher
iv
line
venou
cathet
maintain
fluid
resuscit
avail
necessari
event
sign
renal
failur
hypotens
fever
treat
acetaminophen
maximum
allow
daili
dose
antibiot
indic
recommend
use
nonsteroid
antiinflammatori
medic
nephrotox
agent
avoid
possibl
follow
laboratori
test
perform
daili
rdv
therapi
serum
chemistriesinclud
electrolyt
renal
function
test
creatinin
crcl
bun
liver
function
test
includ
alt
ast
total
bilirubin
alkalin
phosphatas
hematolog
complet
blood
count
prothrombin
time
urinalysi
cov
pcr
avail
perform
regular
interv
monitor
respons
rdv
therapi
continu
weigh
risk
benefit
patient
lab
clinic
paramet
check
discret
physician
avail
laboratori
clinic
result
share
daili
drug
manufactur
gilead
via
either
provid
clinic
updat
form
electron
ecrf
action
plan
advers
event
abnorm
laboratori
result
discuss
gilead
physic
examin
vital
sign
monitor
least
daili
concomit
administr
investig
agent
permit
receiv
remdesivir
gilead
notifi
prior
studi
drug
discontinu
medic
feasibl
remdesivir
perman
discontinu
follow
condit
current
investig
agent
demonstr
clinic
efficaci
approv
treatment
acut
sever
cov
infect
time
assess
safe
effect
antivir
agent
work
directli
select
block
viru
replic
broadli
efficaci
human
pathogen
cov
would
address
seriou
unmet
medic
need
benefit
infect
individu
affect
commun
nonclin
anim
studi
toxic
find
consist
dosedepend
revers
kidney
injuri
dysfunct
clinic
signific
nephrotox
note
anim
speci
unknown
etiolog
revers
kidney
injuri
observ
rat
consist
abil
rat
renal
organ
anion
transport
oat
human
oat
effici
interact
blood
metabolit
remdesivir
particularli
effect
may
lead
proport
higher
intracellular
accumul
drug
metabolit
renal
rat
tubul
lead
kidney
injuri
mg
load
dose
g
sulfobutyleth
sodium
sbecd
day
follow
mg
rdv
day
day
g
sbecd
within
rang
daili
sbecd
administr
consid
safe
human
total
mgkgday
sbecd
consid
safe
european
medicin
agenc
therefor
safe
adult
weight
kg
mg
dose
prepar
salin
hyperton
rel
human
serum
osmol
approach
normal
physiolog
osmolar
rang
human
renal
function
readili
monitor
standard
clinic
chemistri
test
prevail
iv
doubleblind
random
twophas
placebocontrol
phase
ii
trial
rdv
dose
mg
daili
day
design
assess
antivir
activ
longerterm
clearanc
semin
ebov
rna
safeti
liberian
guinean
men
persist
ebov
rna
semen
studi
enrol
plan
particip
receiv
rdv
sae
studi
allow
blind
dose
reduct
transaminas
elev
individu
dose
reduct
rdv
arm
placebo
arm
first
confirm
case
us
previous
healthi
man
return
wuhan
china
admit
provid
region
medic
center
washington
state
histori
cough
subject
fever
holshu
patient
test
posit
ill
day
progress
pneumonia
ill
day
develop
atyp
pneumonia
ill
day
patient
treat
remdesivir
ae
observ
associ
administr
ill
day
patient
afebril
symptom
resolv
except
cough
resolv
current
data
avail
interact
rdv
investig
agent
administ
rdv
concurr
investig
anticov
agent
may
lead
antagon
synergi
effect
overal
toxicolog
studi
cynomolgu
monkey
rat
safeti
pharmacokinet
studi
healthi
human
volunt
patient
ebov
infect
support
safeti
rdv
propos
dose
consider
inform
includ
protocol
overal
risk
patient
outweigh
potenti
benefit
rdv
experiment
therapi
treatment
potenti
coronaviru
infect
conclus
rdv
favor
safeti
profil
support
evalu
propos
dose
regimen
potenti
efficaci
patient
infect
cov
form
complet
via
email
edc
http
wwwimedidatacom
unavail
site
prompt
gilead
clinic
oper
pleas
provid
much
inform
possibl
submit
remdesivircdm
gileadcom
